Structural Formula (Dal00 0006 01)
Daliresp Tablet
Product Images NDC 0310-0095
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Daliresp (NDC 0310-0095). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Daliresp 500 Mcg 30 Count Tablets
This is a medication information label for a drug called "Daliresp" which comes in tablet form with a strength of 20mg (roflumilast). It is manufactured by AstraZeneca and comes in a bottle with 30 tablets. Each tablet contains 500mcg of the active ingredient. The label recommends dispensing the medication guide to each patient along with the medication.*
Dalriesp 250 Mcg 28 Day Pack
The text provides information about a medicine called "Daliresp" or "roflumilast" which comes in a package containing 28 tablets that is child-resistant. The tablets are produced by AsfraZeneca.*
Figure 1
This is a list of drugs indicating whether they require caution, dose adjustment or are not recommended for use with Roflumilast or Roflumilast N-oxide based on the change in Cmax (maximum concentration) and AUC (area under the concentration-time curve) values. Some drugs like budesonide, Digoxin, Formoterol, Maalox, Midazolam, Montelukast, Salbutamol, sildenafil, Theophylline and Warfarin do not require any dose adjustment. However, Rifampicin is not recommended for use with Roflumilast.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
